Triesta Sciences, a unit of HealthCare Global (HCG) Enterprises Limited is the state-of-the-art, one-stop solution for cancer diagnostics, genomics (next-generation sequencing-based diagnostics) biomarker and translational research, laboratory services and clinical research services. Based out of Bangalore, Triesta Sciences is an integration of laboratory services, research and development and clinical research with a focus on innovation, quality and accuracy for better diagnosis and prognosis of cancer.
Triesta reference laboratory is the leading CAP & NABL accredited high-end oncology diagnostic laboratory service provider in the country offering a comprehensive range of routine to highly specialised diagnostic tests for hospitals, medical institutions within India and overseas.
The histopathology laboratory of Triesta Sciences, Bangalore, is the reference lab for the HCG network. It is spread over an area of 1800 sq.ft and is well equipped with state-of-the-art equipment. This lab serves as the centre of excellence for histopathology throughout the network of HCG. The lab receives over 20,000 histopathology specimens a year from its network hospitals as well as outside referral.
The laboratory provides basic histopathology services, Immunohistochemistry, cytology, frozen section, and digital pathology services. There are over 180 immunohistochemistry markers of diagnostics, prognostics, and therapeutic significance, including markers like ALK D5F3, PDL1, MSI etc., supporting the practice of precision oncology. The laboratory also provides LBC services.
The laboratory is the first 100% Digital Pathology laboratory in India for primary diagnosis and implementation of AIML based breast biomarker algorithm for clinical use.
The laboratory supports national and international collaboration for remote reporting of histopathology cases.
Triesta Sciences is equipped with state-of-the-art equipment in histopathology from reputed manufacturers like Leica, Thermo Fisher and Sakura. The laboratory has an FDA approved fully automated immunohistochemistry machine for all its IHC markers. HCG is equipped with a US FDA approved digital pathology scanner from Philips, with its image management system and central portal server.
HCG is recognised and awarded as the first 100% digital pathology laboratory for primary diagnosis in India since October 2018.
The laboratory has completely embraced a digital workflow ensuring 100% patient safety, accurate staging and grading of tumours, saving logistics cost, collaboration, and improved efficiency. It is the first laboratory in the country to implement an IVDCE approved, artificial intelligence machine learning-based (AIML) algorithm for objective interpretation of breast biomarkers.
The laboratory has been accredited by the College of American pathologists (CAP) and NABL based on ISO 015 189 2012 standard, for the last 8-10 years.
The histopathology laboratory is the first in the country to get these accreditations with digital pathology and image-based artificial intelligence machine learning breast biomarker algorithm, in its scope of accreditation.
There are 12 histopathologists in the HCG network. The Bangalore centre has three pathologists who practice organ-specific sub-speciality histopathology reporting. They are well qualified and highly experienced in the field of oncopathology. They are also trained in generating reports for digital pathology images (WSIs), remotely. There are three senior residents who are post-MD, doing their fellowship in tumour pathology, as well as eight junior DNB residents. There are seven highly skilled histopathology and immunohistochemistry technicians along with a digital pathology coordinator. This technical team is well supported by the customer care and front office executives.
The pathologists in HCG are experts in organ systems and practice subspeciality organ-specific reporting. Internal team discussions supported by a vast gamut of IHC and genomics ensures a strong objective evidence-based diagnosis. This ensures the practice of precision oncology. The pathologists regularly participate in clinical case discussions and MDTs, thereby contributing to efficient patient management.
Digital Pathology: A Revolution in the Field of Cancer Diagnosis and Treatment
Triesta Sciences, a division of HealthCare Global Enterprises, was the first referral laboratory in India to use digital pathology for primary diagnosis in histopathology. With a network of 24 oncology centres across India and abroad, and a talented pool of histopathologists, the need for integrating all the centres to provide a uniform standard of reporting was envisioned by Dr. BS Ajaikumar, Executive Chairman, HCG.
This vision became reality with the implementation of digital pathology in the HCG network. Through organ-specific reporting by subspecialist histopathology experts, this approach aims at delivering superior diagnostic support within a short turnaround time saving on logistics.
Fig 1: Digital Pathology Set-up
Since October 2018, digital images / whole slide images generated on FDA approved digital pathology scanner, are the mode of primary diagnosis in histopathology in the Triesta referral lab in HCG, Bangalore. The entire caseload of the day is digitised providing whole slide images that provide tools for accurate measurements for staging and quantification of tumours, counting mitoses, interpretation of lymphovascular and perineural invasion accurately, along with identification of isolated tumour cells, micro-metastasis or macro-metastasis, major or minor extracapsular extension etc. The pathologists are extensively trained on reporting on whole slide images and have a diagnostic concordance of 99.7%.